title: Bone mass behavior after 1 year of different treatment strategies in prostate cancer patients subjected to androgen deprivation therapy.
abstract: The aim of this study was to evaluate bone mass changes after 1 year of four different types of pharmacological intervention. Ninety-seven prostate cancer patients treated with androgen deprivation therapy, and severe osteopenia or osteoporosis were retrospectively studied. Patients were divided in four groups. Group 1: 28 patients treated with denosumab, Group 2: 24 patients treated with alendronate, Group 3: 24 patients with no antiresorptive treatment and Group 4: 21 patients previously treated with alendronate and switched to denosumab. Dual X-ray absorptiometry was performed at baseline and after 1 year. Bone mass changes at the L2-L4 lumbar spine, femoral neck and total hip were evaluated. No differences were found at baseline. After 1 year, men receiving denosumab or alendronate (Group 1 and 2) showed a significant bone mass increase at the lumbar spine (+2.4 and +5.0 %, respectively), while no significant changes were observed in Group 3 and 4. At the femoral neck, Group 1 and 2 patients showed a significant bone mass increase (+3.7 and +3.6 %, respectively), while no significant changes were observed in Group 3 and 4. At the total hip, we observed a significant bone mass increase in Group 1 (+2.9 %) and a significant bone mass loss in Group 3 patients (-1.9 %). No significant changes were observed in Group 2 and 4. Denosumab increased significantly bone mass in all three dual X-ray absorptiometry standard sites, while alendronate did not at total hip. No benefit was observed in men previously treated with alendronate who switched to denosumab treatment.
authors.affiliation: Department of Urology, Hospital Vall d'Hebrón, Universitat Autònoma de Barcelona, Passeig de la Vall d'Hebrón 119-129, 08035, Barcelona, Spain, jacquesplanas@gmail.com.
authors.forename: J
authors.initials: J
authors.lastname: Planas Morin
authors.forename: A
authors.initials: A
authors.lastname: Celma Domenech
authors.forename: J
authors.initials: J
authors.lastname: Placer Santos
authors.forename: E
authors.initials: E
authors.lastname: Trilla Herrera
authors.forename: C
authors.initials: C
authors.lastname: Salvador Lacambra
authors.forename: D
authors.initials: D
authors.lastname: Lorente Garcia
authors.forename: L
authors.initials: L
authors.lastname: Regis
authors.forename: J
authors.initials: J
authors.lastname: Carles Galceran
authors.forename: J
authors.initials: J
authors.lastname: Morote Robles
mesh_terms: D000368:Aged; D000369:Aged, 80 and over; D019386:Alendronate / Q000627:therapeutic use*; D000726:Androgen Antagonists / Q000009:adverse effects* / Q000627:therapeutic use; D000813:Anilides / Q000009:adverse effects* / Q000627:therapeutic use; D061067:Antibodies, Monoclonal, Humanized / Q000627:therapeutic use*; D050071:Bone Density Conservation Agents / Q000627:therapeutic use*; D001851:Bone Diseases, Metabolic / Q000139:chemically induced / Q000000981:diagnostic imaging / Q000188:drug therapy*; D000069448:Denosumab; D005272:Femur Neck / Q000000981:diagnostic imaging; D006801:Humans; D016729:Leuprolide / Q000009:adverse effects* / Q000627:therapeutic use; D008159:Lumbar Vertebrae / Q000000981:diagnostic imaging; D008297:Male; D009570:Nitriles / Q000009:adverse effects* / Q000627:therapeutic use; D010024:Osteoporosis / Q000139:chemically induced / Q000000981:diagnostic imaging / Q000188:drug therapy*; D011471:Prostatic Neoplasms / Q000188:drug therapy* / Q000473:pathology; D011859:Radiography; D014105:Tosyl Compounds / Q000009:adverse effects* / Q000627:therapeutic use
chemical_list: D000726:Androgen Antagonists; D000813:Anilides; D061067:Antibodies, Monoclonal, Humanized; D050071:Bone Density Conservation Agents; D009570:Nitriles; D014105:Tosyl Compounds; D000069448:Denosumab; C053541:bicalutamide; D016729:Leuprolide; D019386:Alendronate